Biomedical Engineering Reference
In-Depth Information
37. Zheng T, Liu W, Oh SY, Zhu Z, Hu B, Homer RJ, et al. (2008)
IL-13 receptor alpha2 selectively inhibits IL-13-induced
responses in the murine lung. J. Immunol. 180, 522-529.
38. Yi KH, Chen L. (2009) Fine tuning the immune response
through B7-H3 and B7-H4. Immunol. Rev. 229, 145-151.
39. Graham GJ. (2009) D6 and the atypical chemokine receptor
family: novel regulators of immune and inflammatory pro-
cesses. Eur. J. Immunol. 39, 342-351.
40. Eisenberg SP, Brewer MT, Verderber E, Heimdal P, Brand-
huber BJ, Thompson RC. (1991) Interleukin 1 receptor
antagonist is a member of the interleukin 1 gene family:
evolution of a cytokine control mechanism. Proc. Natl. Acad.
Sci. USA 88, 5232-5236.
41. Aizawa Y, Akita K, Taniai M, Torigoe K, Mori T, Nishida Y,
et al. (1999) Cloning and expression of interleukin-18 binding
protein. FEBS Lett. 445, 338-342.
42. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello
CA, Rubinstein M. (1999) Interleukin-18 binding protein: a
novel modulator of the Th1 cytokine response. Immunity
10, 127-136.
43. Blumberg H, Dinh H, Trueblood ES, Pretorius J, Kugler D,
Weng N, et al. (2007) Opposing activities of two novel
members of the IL-1 ligand family regulate skin inflamma-
tion. J. Exp. Med. 204, 2603-2614.
44. Walsh DW, Godson C, Brazil DP, Martin F. (2010) Extrac-
ellular BMP-antagonist regulation in development and dis-
ease: tied up in knots. Trends Cell Biol. 20, 244-256.
45. MacDonald BT, Tamai K, He X. (2009) Wnt/beta-catenin
signaling: components, mechanisms, and diseases. Dev. Cell
17, 9-26.
46. Peppel K, Crawford D, Beutler B. (1991) A tumor necrosis
factor (TNF) receptor-IgG heavy chain chimeric protein as a
bivalent antagonist of TNF activity. J. Exp. Med. 174, 1483-
1489.
47. Capon DJ, Chamow SM, Mordenti J, Marsters SA, Gregory T,
Mitsuya H, et al. (1989) Designing CD4 immunoadhesins for
AIDS therapy. Nature 337, 525-531.
48. Traunecker A, Dolder B, Oliveri F, Karjalainen K. (1989)
Solubilizing the T-cell receptor-problems in solution. Immu-
nol. Today 10, 29-32.
49. Traunecker A, Schneider J, Kiefer H, Karjalainen K. (1989)
Highly efficient neutralization of HIV with recombinant
CD4-immunoglobulin molecules. Nature 339, 68-70.
50. Carter PJ. (2006) Potent antibody therapeutics by design. Nat.
Rev. Immunol. 6, 343-357.
51. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB,
Wong EL, Ryder AM, et al. (1995) Expression and charac-
terization of CD4-IgG2, a novel heterotetramer that neutral-
izes primary HIV type 1 isolates. AIDS Res. Hum.
Retroviruses 11, 533-539.
52. Mohler KM, Torrance DS, Smith CA, Goodwin RG,
Stremler KE, Fung VP, et al. (1993) Soluble tumor necrosis
factor (TNF) receptors are effective therapeutic agents in
lethal endotoxemia and function simultaneously as both
TNF carriers and TNF antagonists. J.
53. Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-
Stec EM, Hartnett C, et al. (2003) Cytokine Traps: multi-
component, high-affinity blockers of cytokine action. Nat.
Med. 9, 47-52.
54. Feldmann M, Maini RN. (2003) Lasker Clinical Medical
Research Award. TNF defined as a therapeutic target for
rheumatoid arthritis and other autoimmune diseases. Nat.
Med. 9, 1245-1250.
55. Maini RN, Taylor PC. (2000) Anti-cytokine therapy for
rheumatoid arthritis. Annu. Rev. Med. 51, 207-229.
56. Ducharme E, Weinberg JM. (2008) Etanercept. Expert Opin.
Biol. Ther. 8, 491-502.
57. Prodanovich S, Ricotti C, Glick BP, Inverardi L, Leonardi CL,
Kerdel F. (2010) Etanercept: an evolving role in psoriasis and
psoriatic arthritis. Am. J. Clin. Dermatol. 11(Suppl. 1), 3-9.
58. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R.
(2010) Meta-analysis of the efficacy and safety of adalimu-
mab, etanercept, and infliximab for the treatment of rheuma-
toid arthritis. Pharmacotherapy 30, 339-353.
59. Tansey MG, Szymkowski DE. (2009) The TNF superfamily
in 2009: new pathways, new indications, and new drugs. Drug
Discov. Today 14, 1082-1088.
60. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA,
Fleischmann RM, Weaver AL, et al. (1997) Treatment of
rheumatoid arthritis with a recombinant human tumor necro-
sis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med.
337, 141-147.
61. Moreland LW. (2001) Tumor necrosis factor inhibitors: new
options for treating rheumatoid arthritis. Isr. Med. Assoc. J. 3,
686-690.
62. Stahl N, Radin A, Mellis S. (2009) Rilonacept-CAPS and
beyond. Ann. NY Acad. Sci. 1182, 124-134.
63. Hoffman HM, Throne ML, Amar NJ, Sebai M, Kivitz AJ,
Kavanaugh A, et al. (2008) Efficacy and safety of rilonacept
(interleukin-1 Trap) in patients with cryopyrin-associated
periodic syndromes: results from two sequential placebo-
controlled studies. Arthritis Rheum. 58, 2443-2452.
64. Hoffman HM. (2009) Rilonacept for the treatment of cry-
opyrin-associated periodic syndromes (CAPS). Expert Opin.
Biol. Ther. 9, 519-531.
65. N. Papadopoulos, J. Martin, Q. Ruan, A. Rafique, M. P.
Rosconi, E. Shi, E. A. Pyles, G. D. Yancopoulos, N. Stahl,
S. J. Wiegand. (2012). Binding and neutralization of vascular
endothelial growth factor (VEGF) and related ligands by
VEGF Trap, ranibizumab and bevacizumab. Angiogenesis,
15, 171-185.
66. Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P,
Sullivan-Whalen M, et al. (2007) Alefacept (anti-CD2)
causes a selective reduction in circulating effector memory
T cells (Tem) and relative preservation of central memory T
cells (Tcm) in psoriasis. J. Transl. Med. 5, 27-33.
67. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, Gilleau-
deau P, et al. (2005) Alefacept reduces infiltrating T
cells, activated dendritic cells, and inflammatory genes
in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 102,
2075-2080.
Immunol. 151,
1548-1561.
Search WWH ::




Custom Search